Protein kinase C-β-dependent changes in the glucose metabolism of bone marrow stromal cells of chronic lymphocytic leukemia Franziska von Heydebrand, Maximilian Fuchs, Meik Kunz, Simon Voelkl, Anita N. Kremer, Robert A. J. Oostendorp, Jochen Wilke, Michael Leitges, Alexander Egle, Andreas Mackensen, Gloria Lutzny-Geier First published: 04 February 2021

A brief Instrument to measure health-related quality-of-life in patients with bone metastasis: validation of the German version of Bone Metastases Quality-of-Life-10 (BOMET-Qol-10) Marschner, N., Wilke, J., Reschke. D., Kaiser, F., Schmoor. C., Grugel. R., Boiler. E. J Med Econ. 2018 Jun 18:1-10. doi: 10.1080/13696998.2018.1484750.

Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: A Randomized Multicenter Phase II Trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group Jalid Sehouli, Dirk Stengel, Philipp Harter, Christian Kurzeder, Antje Belau, Thomas Bogenrieder, Susanne Markmann, Sven Mahner, Lothar Mueller, Ralf Lorenz, Andreas Nugent, Jochen Wilke, Andreas Kuznik, Gabriele Doering, Arthur Wischnik, Harald Sommer, Hans-Gerd Meerpohl, Willibald Schroeder, Werner Lichtenegger, and Guelten Oskay-Oezcelik J Clin Oncol, January 10, 2011 vol. 29:242-248.

Trastuzumab treatment of early breast cancer: Long-term results from a prospective observation study, including a large cohort of elderly patients P Dall, G Lenzen, T Göhler, G Feisel-Schwickeradi, T Koch, V Heilmann, C Schindler, J Wilke, H Tesch, J Selbach, J Eggert, and A Hinke Cancer Res 2013;73(24 Suppl): Abstract nr P2-15-02.

Trastuzumab in the treatment of elderly patients with early breast cancer: Results from a observational study in Germany P Dall, G Lenzen, T Göhler, G Feisel-Schwickeradi, T Koch, V Heilmann, C Schindler, J Wilke, H Tesch, J Selbach, J Eggert, and A Hinke J Geriatr Oncol (2015) Nov;6(6):462-9.

Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. Sehouli J. Stengel D, Harter P, Kurzeder C, Belau A, Bogenrieder T, Markmann S, Mahner S, Mueller L, Lorenz R, Nugent A, Wilke J, Kuznik A, Doering G, Wischnik A, Sommer H, Meerpohl HG, Schroeder W, Lichtenegger W, Oskay-Oezcelik G. J Clin Oncol. 2011 Jan 10;29(2):242-8.

Ribociclib + letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative, advanced breast cancer (ABC) who received no prior therapy for advanced disease Janni W., Nusch A., Grischke E.-M., Marschner N., Wilke J., Decker T., Abenhardt W., Kurbacher C., Overkamp F., Just M., Kümmel S., Marmé F., Xuan F., Miller M., Sonke G.S. Oncol Res Treat 2016;39(suppl 3):1-350, S.214-215

Interim results from PAZOREAL: a non-interventional study to assess effectiveness and safety of pazopanib and everolimus in the changing mRCC treatment landscape J. Bedke, M. Welslau, M. Boegemann, M. Schostak, C. Hering-Schubert, A. Petzoldt, T. Wolf, J. Schleicher, C. Doehn, C. Grüllich, V. Grünwald, T. Steiner, R. Ehness, D. Klein, T. Medinger, P.J. Goebell Annals of Oncology (2017) 28 (suppl_5): v295-v329. 10.1093/annonc/mdx371